Table 6.

Clinical follow-up (32 patients)

ParameterValue
Duration of follow-up (mo; mean [range])30.3 (1.0 to 114.0)
Treatment
    none5 (15.6)
    RAS blockade alone9 (28.1)
    IM18 (56.3)
        steroids11
        cyclophosphamide3
        cyclosporine2
        mycophenolate mofetil5
        rituximab4
        chlorambucil1
        thalidomide2
        bortezomib (Velcade)1
Outcomea
    CR4 (12.5)
    PR8 (25.0)
    PRD12 (37.5)
    Persistent hematuria (with normal creatinine and no proteinuria)1 (3.1)
    ESRD7 (21.9)
    Death5 (15.6)
  • aCR: Remission of proteinuria to <500 mg/d with normal renal function; PR: Reduction in proteinuria by at least 50% and to <2 g/d with stable renal function (no more than a 20% increase in serum creatinine); PRD: Failure to meet criteria for either CR or PR but not reaching ESRD, including patients with unremitting proteinuria, or progressive chronic kidney disease.